Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON53326Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elranatamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities, Sustained MRD negativity rate and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
elranatamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53326.